Apalutamide Recruiting Phase 1 Trials for Castration-Resistant Prostatic Neoplasms Treatment

IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT03551782A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer